OmniAb, Inc.

OmniAb, Inc. is a biotechnology company focused on antibody discovery technology, formed through the de-SPAC merger of Avista Public Acquisition Corp. II (Nasdaq: AHPA) with OmniAb, a business unit spun out of Ligand Pharmaceuticals. The SPAC was sponsored by Avista Capital Partners and completed its IPO in 2021. The 10-Q filed on August 12, 2022, under accession 0001104659-22-089508, was submitted during the pre-closing period, ahead of the business combination's completion in October 2022, after which the combined company traded on Nasdaq under the ticker OABI. OmniAb operates in the life sciences and biotechnology sector, licensing its antibody discovery platform to biopharmaceutical partners worldwide. Sign up for SpacDesk to access the full filing history, deal analytics, and data coverage for OmniAb and hundreds of other SPAC transactions.